Abstract:Abstract Background Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME) that play an important role in cancer progression. Although the mechanism by which CAFs promote tumorigenesis has been well investigated, the underlying mechanism of CAFs activation by neighboring cancer cells remains elusive. In this study, we aim to investigate the signaling pathways involved in CAFs activation by gastric cancer cells (GC) and to provide insights into the therapeutic targeting of CAFs for overcoming GC. Methods Alteration of receptor tyrosine kinase (RTK) activity in CAFs was analyzed using phospho-RTK array. The expression of CAFs effector genes was determined by RT-qPCR or ELISA. The migration and invasion of GC cells co-cultured with CAFs were examined by transwell migration/invasion assay. Results We found that conditioned media (CM) from GC cells could activate multiple receptor tyrosine kinase signaling pathways, including ERK, AKT, and STAT3. Phospho-RTK array analysis showed that CM from GC cells activated PDGFR tyrosine phosphorylation, but only AKT activation was PDGFR-dependent. Furthermore, we found that connective tissue growth factor (CTGF), a member of the CCN family, was the most pronouncedly induced CAFs effector gene by GC cells. Knockdown of CTGF impaired the ability of CAFs to promote GC cell migration and invasion. Although the PDGFR-AKT pathway was pronouncedly activated in CAFs stimulated by GC cells, its pharmacological inhibition affected neither CTGF induction nor CAFs-induced GC cell migration. Unexpectedly, the knockdown of SRC and SRC-family kinase inhibitors, dasatinib and saracatinib, significantly impaired CTGF induction in activated CAFs and the migration of GC cells co-cultured with CAFs. SRC inhibitors restored the reduced expression of epithelial markers, E-cadherin and Zonula Occludens-1 (ZO-1), in GC cells co-cultured with CAFs, as well as CAFs-induced aggregate formation in a 3D tumor spheroid model. Conclusions This study provides a characterization of the signaling pathways and effector genes involved in CAFs activation, and strategies that could effectively inhibit it in the context of GC.

Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity

The Diverse Functions and Therapeutic Implications of Cancer-Associated Fibroblasts in Colorectal Cancer

Cancer‐associated Fibroblasts in Breast Cancer: Challenges and Opportunities

Connective Tissue Growth Factor: From Molecular Understandings to Drug Discovery

Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy

Regulation, Diseases, and Drug Discovery

Targeting TGF-β signal transduction for fibrosis and cancer therapy

Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities

Targeting cytokine and chemokine signaling pathways for cancer therapy

Unlocking the Crucial Role of Cancer-Associated Fibroblasts in Tumor Metastasis: Mechanisms and Therapeutic Prospects

Targeting TGFβ signal transduction for cancer therapy

Targeting FGFR for cancer therapy

The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Recent advances in cancer-associated fibroblast: Biomarkers, signaling pathways, and therapeutic opportunities

Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach

TGF-&beta; Signaling in Cancer Metastasis

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review